Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Efsubaglutide improves diabetes control with metformin
Last updated September 12, 2026
Key finding
HbA1c decreased by 1.43% with 3 mg (p < 0.0001).
Efsubaglutide alfa significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metformin.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Efsubaglutide alfa significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metformin.
Clinical relevance
These findings are significant as they suggest that efsubaglutide could be a valuable addition to the treatment options for adults with type 2 diabetes who are not achieving adequate glycaemic control with metformin alone. Improved glycaemic control can lead to better long-term health outcomes and reduce the risk of diabetes-related complications.
Keep in mind
The study's population may not be representative of all adults with type 2 diabetes. The duration of the study may not capture long-term effects. Potential biases in self-reported data on weight and glycaemic control.
Published in
Journal Reference
Publication details and source links for this paper.
Weiping J, Fei G, Jingyi L, et al. Efsubaglutide alfa improves glycaemic control in adults with type 2 diabetes inadequately controlled on metformin. Nature Communications. 2026;17:6222. doi:10.1038/s41467-026-72574-7
Main Effects
HbA1c decreased by 1.43% with efsubaglutide (p < 0.0001).
Fasting plasma glucose decreased by 2.42 mmol/L with efsubaglutide (p < 0.001).
Body weight decreased by 2.74 kg with efsubaglutide (p < 0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Efsubaglutide 3 mg and Body weight, Fasting Plasma Glucose (FPG), HbA1c.
This study contributes evidence to
Primary intervention
Efsubaglutide 3 mg
Primary outcomes
- Body weight
- Fasting Plasma Glucose (FPG)
- HbA1c
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
3
Evidence pairs
3
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
4
Related topics
3
Evidence pairs
1865
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 3 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
Fasting Blood Glucose
matched_outcome
Related evidence
Evidence topic
Glycemic Control
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Fasting Plasma Glucose (FPG)
Efsubaglutide 3 mg → Fasting Plasma Glucose (FPG)
Efsubaglutide 3 mg → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Efsubaglutide reduced HbA1c by 1.43%, significantly more than placebo.
- Fasting plasma glucose decreased by 2.42 mmol/L with efsubaglutide.
- Body weight decreased by 2.74 kg in the efsubaglutide group.
Who this applies to
- Adults with type 2 diabetes inadequately controlled on metformin.
- Individuals seeking additional treatment options for glycaemic control.
Keep in Mind
- Results may not apply to individuals not on metformin.
- Further studies are needed to assess long-term safety and efficacy.
- The study's findings are based on a specific population and may not generalize.
Between the Lines
- The study's population may not be representative of all adults with type 2 diabetes.
- The duration of the study may not capture long-term effects.
- Potential biases in self-reported data on weight and glycaemic control.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Efsubaglutide 3 mg and Body Weight, Efsubaglutide 3 mg and Fasting Glucose.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Efsubaglutide 3 mg → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Efsubaglutide 3 mg → Fasting Glucose
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
Efsubaglutide 3 mg Evidence Hub
All studies on Efsubaglutide 3 mg
1 studies
intervention_hubContributes to Efsubaglutide 3 mg evidence base.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
1 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Efsubaglutide 3 mg and Body weight
Intervention: Efsubaglutide 3 mgOutcome: Body weight
1 results
All studies on Efsubaglutide 3 mg and Fasting Plasma Glucose (FPG)
Intervention: Efsubaglutide 3 mgOutcome: Fasting Plasma Glucose (FPG)
1 results
All studies on Efsubaglutide 3 mg
Intervention: Efsubaglutide 3 mg
1 results
All studies measuring Body weight
Outcome: Body weight
1 results
All studies measuring Fasting Plasma Glucose (FPG)
Outcome: Fasting Plasma Glucose (FPG)
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Efsubaglutide 3 mg affect body weight?
Emerging Evidence
Efsubaglutide 3 mg appears to affect body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Efsubaglutide 3 mg improve fasting plasma glucose (FPG)?
Emerging Evidence
Efsubaglutide 3 mg appears to improve fasting plasma glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Efsubaglutide 3 mg lower HbA1c?
Emerging Evidence
Efsubaglutide 3 mg appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.Exercise Improves Serum Albumin Levels in Women with Type 2 DiabetesHRS-7535 improves glycemic control in adults with type 2 diabetesBariatric surgery improves glucose homeostasis in type 2 diabetes.CT-868 Improves Glycaemic Control in Type 2 Diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.